-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compileriver
A few days ago, according to foreign media reports, Bristol-Myers Squibb (BMS) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended to grant Abecma (idecabtagene vicleucel, ide-cel) conditional marketing authorization
CHMP adopted positive opinions based on the results of the pivotal Phase II KarMMa study, which evaluated the efficacy and safety of Abecma in 128 patients with severe pre-treatment and highly refractory multiple myeloma
The results showed that in the efficacy evaluation population (n=100), the overall response rate (ORR) of Abecma single infusion therapy was 72% (95%CI: 62-81), and 28% of patients achieved strict complete remission ( sCR; 95%CI: 19-38)
In this study, the safety of Abecma in treated patients has been well confirmed.
It is worth mentioning that Abecma is the world's first BCMA-directed CAR-T cell therapy to receive regulatory approval.
EC expects to make a final decision within 67 days after receiving the CHMP opinion
Reference source:
1.
2.